Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pituitary adenoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Pituitary adenoma. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2009-010787-42 Sponsor Protocol Number: 2-55-52060-003 Start Date*: 2009-09-02
    Sponsor Name:Ipsen Pharma
    Full Title: PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACR...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) FR (Completed) LT (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000265-43 Sponsor Protocol Number: München/CS04 Start Date*: 2018-05-30
    Sponsor Name:Max-Planck-Institut für Psychiatrie
    Full Title: A randomized, placebo-controlled trial comparing the treatment effect of Pegvisomant and the SSRI Escitalopram on depressive acromegalic patients
    Medical condition: Acromegalie with depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2007-005244-25 Sponsor Protocol Number: GH-2007-228 Start Date*: 2008-01-31
    Sponsor Name:Aarhus University Hospital, Department M
    Full Title: Co-treatment with pegvisomant and a somatostatin analogue (SA) in SA-responsive acromegalic patients: impact on insulin sensitivity, glucose tolerance, and pharmacoeconomics
    Medical condition: Acromegaly Insulin resistence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    9.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002619-25 Sponsor Protocol Number: P061012 Start Date*: 2007-09-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: "Physiopathologie de la rétention rénale de sodium dans l'acromégalie" -Etude ACROMENAC
    Medical condition: Acromégalie
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000599 Acromégalie PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004498-34 Sponsor Protocol Number: SUM Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodie...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023674-39 Sponsor Protocol Number: AKRO1 Start Date*: 2014-08-05
    Sponsor Name:Österreichisches Akromegalie Register
    Full Title: Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002389-62 Sponsor Protocol Number: 8-55-52030-309 Start Date*: 2015-03-02
    Sponsor Name:Ipsen Group
    Full Title: Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects wi...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) LT (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002630-31 Sponsor Protocol Number: CSOM230C2413 Start Date*: 2015-03-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin ana...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000267-84 Sponsor Protocol Number: CSOM230B2412 Start Date*: 2013-06-07
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continue...
    Medical condition: Cushing’s disease Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    14.1 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000533-12 Sponsor Protocol Number: HS-12-455 Start Date*: 2014-07-02
    Sponsor Name:Camurus AB
    Full Title: A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NE...
    Medical condition: acromegaly; neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001191-11 Sponsor Protocol Number: HS-18-633 Start Date*: 2020-02-13
    Sponsor Name:Camurus AB
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001833-42 Sponsor Protocol Number: CRN00808-02 Start Date*: 2018-11-13
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR o...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GR (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-002230-20 Sponsor Protocol Number: CRN00808-03 Start Date*: 2018-11-13
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) DE (Completed) GR (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004956-12 Sponsor Protocol Number: CORT125134-456 Start Date*: 2021-02-24
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-...
    Medical condition: Hypercortisolism
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BG (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000748-32 Sponsor Protocol Number: SPI-62-CL-2002 Start Date*: 2023-08-29
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
    Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 07:10:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA